Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
May 8, 2017
- Luspatercept MEDALIST and BELIEVE Phase 3 trials expected to complete enrollment in Q2 2017 - - Presented results from ongoing Phase 2 trial with luspatercept at the 14th International Symposium on MDS - - Announced plans to initiate luspatercept Phase 3 trial in first-l...
May 6, 2017
- Preliminary results show that treatment with investigational drug luspatercept achieves meaningful erythroid response rates and transfusion independence in first-line, lower-risk myelodysplastic syndromes patients - - Celgene and Acceleron plan to initiate a Phase 3 trial in first-line,...
May 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that Steven Ertel, due to medical reasons, will transition...
May 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Apr 27, 2017
- Enrollment in MEDALIST and BELIEVE Phase 3 studies now expected to be completed in Q2 2017 - - Acceleron and Celgene to initiate an additional Phase 3 trial in first-line, lower-risk MDS in early 2018 to expand opportunity beyond ongoing MEDALIST study - CAMBRIDGE,...
Apr 26, 2017
- Management to review highlights from luspatercept clinical presentations at the 14th International MDS Symposium - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commerci...
Apr 6, 2017
Oral presentation highlights new Phase 2 data in additional sub-populations of lower-risk MDS CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative...
Mar 16, 2017
- Second Phase 2 study for ACE-083 expected to begin 2H 2017 - - Company to host educational webinar with leading clinical researcher on April 3rd at 11:00 a.m. EDT - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
Mar 1, 2017
- Luspatercept Phase 3 trials to complete enrollment in both the MDS ("MEDALIST") and beta-thalassemia ("BELIEVE") trials in 2H 2017 - - Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December - - Treated f...
Feb 28, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Feb 22, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webca...
Feb 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Jan 6, 2017
- Luspatercept MEDALIST Phase 3 trial in MDS expected to complete enrollment in the 2nd half of 2017 - - Luspatercept BELIEVE Phase 3 trial in beta-thalassemia expected to complete enrollment in the 2nd half of 2017 - - Plan to initiate new luspatercept Phase 2 clinical trials in ...
Jan 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, wil...
Dec 22, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the first patient has been treated in a Phase 2 clinic...
= add release to Briefcase